Aids dementia complex: Diagnosis and drug treatment options

CNS Drugs

Volumn 9, Issue 1, 1998, Pages 31-40

  Portegies, Peter ^a,b   Rosenberg, Nathalie R ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; LOVIRIDE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CEREBROSPINAL FLUID ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DEMENTIA; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RETROVIRUS; REVIEW; VIRUS REPLICATION;

EID: 0031939071     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199809010-00004     Document Type: Review

References (59)

1. Navia BA, Jordan BD, Price RW, et al. The AIDS dementia complex: I. Clinical features. Ann Neurol 1986; 19: 517-24
2. Navia BA, Cho E-S, Petito CK, et al. The AIDS dementia complex: II. Neuropathology. Ann Neurol 1986; 19: 525-35
3. Price RW, Brew B, Sidtis J, et al. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science 1988; 239: 586-92
4. Price RW. Management of AIDS dementia complex and HIV-1 infection of the nervous system. AIDS 1995; 9 Suppl. A: S221-36
5. Gray F, Lescs MC, Keohane C, et al. Early brain changes in HIV infection: neuropathological study of 11 HIV seropositive, non-AIDS cases. J Neuropathol Exp Neurol 1992; 51: 177-85
6. Epstein LG, Gendelman HE. Human immunodeficiency virus type 1 infection of the nervous system: pathogenetic mechanisms. Ann Neurol 1993; 33: 429-36
7. Foudraine N, de Wolf F, Hoetelmans R, et al. CSF and serum HIV-RNA levels during AZT/3TC and d4T/3TC treatment [abstract]. 4th Conference on Retroviruses and Opportunistic Infections: 1997 Jan 22-26; Washington, DC, LB5
8. Wiley CA, Schrier RD, Nelson JA, et al. Cellular localization of human immunodeficiency virus infection within the brains of acquired immunodeficiency patients. Proc Natl Acad Sci USA 1986; 83: 7089-93
9. Sharer LR. Pathology of HIV-1 infection of the central nervous system: a review. J Neuropathol Exp Neurol 1992; 51: 3-11
10. Achim CL, Wiley CA. Inflammation in AIDS and the role of the macrophage in brain pathology. Curr Opin Neurol 1996; 9: 221-5
11. Pumarola-Sune T, Navia BA, Cordon-Cardo C, et al. HIV antigen in the brains of patients with the AIDS dementia complex. Ann Neurol 1987; 21: 490-6
12. Brew BJ, Rosenblum M, Cronin K, et al. AIDS dementia complex and HIV-1 brain infection: clinical-virological correlations. Ann Neurol 1995; 38: 563-70
13. Adamson DC, Wildemann B, Saski M, et al. Immunologic NO synthase: elevation in severe AIDS dementia and induction by HIV-1 gp41. Science 1996; 274: 1917-21
14. McArthur JC. Neurologic manifestations of AIDS. Medicine 1987; 66: 407-37
15. Portegies P, Enting RH, de Gans J, et al. Presentation and course of AIDS dementia complex: 10 years of follow-up in Amsterdam, The Netherlands. AIDS 1993; 7: 669-75
16. Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis 1988; 158: 1079-83
17. Janssen RS, Cornblath DR, Epstein LG, et al. Nomenclature and research case definitions for neurological manifestations of human immunodeficiency virus type-1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology 1991; 41: 778-85
18. Simpson DM, Tagliati M. Neurologic manifestations of HIV infection. Ann Intern Med 1994; 121: 769-85
19. Olsen WL, Longo FM, Mills CM, et al. White matter disease in AIDS: findings at MR imaging. Radiology 1988; 169: 445-8
20. Ho DD, Rota TR, Schooley RT, et al. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurological syndromes related to the acquired immunodeficiency syndrome. N Engl J Med 1985; 313: 1493-7
21. Portegies P, Epstein LG, Tjong A, et al. Human immunodeficiency virus type I antigen in cerebrospinal fluid: correlation with clinical neurologic status. Arch Neurol 1989; 46: 261-4
22. Brew BJ, Paul MO, Nakajima G, et al. Cerebrospinal fluid HIV-1 p24 antigen and culture: sensitivity and specificity for AIDS dementia complex. J Neurol Neurosurg Psychiatry 1994, 57: 784-9
23. Royal W, Selnes OA, Concha M, et al. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) p24 antigen levels in HIV-related dementia. Ann Neurol 1994, 36: 32-9
24. Van Wielink G, McArthur JC, Moench T, et al. Intrathecal synthesis of anti-HIV IgG: correlation with increasing duration of HIV-1 infection. Neurology 1990; 40: 816-9
25. Heyes MP, Brew BJ, Martin A, et al. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol 1991, 29: 202-9
26. Dunbar N, Brew B. Neuropsychological dysfunction in HIV infection: a review. J Neuro-AIDS 1996; 1: 73-102
27. Power Ch, Selnes OA, Grim JA, et al. HIV dementia scale: a rapid screening test. J Acquir Immune Defic Syndr 1995; 8: 273-8
28. Burger DM, Kraaijeveld CL, Meenhorst PL, et al. Penetration of zidovudine into the cerebrospinal fluid of patients infected with human immunodeficiency virus. AIDS 1993; 7: 1581-7
29. Yarchoan R, Berg G, Brouwers P, et al. Response of human immunodeficiency virus-associated neurological disease to 3′-azido-3′-deoxythymidine. Lancet 1987; 1: 132-5
30. Schmitt FA, Bigley JW, McKinnis R, et al. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1988; 319: 1573-8
31. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morbid Mortal Wkly Rep 1992; 41 (RR-14): 1-4
32. Tozzi V, Narciso P, Galgani S, et al. Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex. AIDS 1993; 7: 683-92
33. Sidtis JJ, Gatsonis C, Price RW, et al. Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. Ann Neurol 1993; 33: 343-9
34. Baldeweg T, Catalan J, Lovett E, et al. Long-term zidovudine reduces neurocognitive deficits in HIV-1 infection. AIDS 1995; 9: 589-96
35. Pizzo PA, Eddy J, Falloon J, et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med 1988; 319: 889-96
36. Nozyce M, Hoberman M, Arpadi S, et al. A 12-month study of the effects of oral zidovudine on neurodevelopmental functioning in a cohort of vertically HIV-infected inner-city children. AIDS 1994; 8: 635-9
37. De Gans J, Lange JMA, Derix MMA, et al. Decline of HIV antigen levels in cerebrospinal fluid during treatment with low-dose zidovudine. AIDS 1988; 2: 37-40
38. Portegies P, Danner SA, Enting RH, et al. Decline of HIV-1 RNA in cerebrospinal fluid during zidovudine treatment [letter]. Antiviral Ther 1996; 1: 195
39. Brew BJ, Bhalla RB, Paul M, et al. Cerebrospinal fluid beta-2-microglobulin in patients with AIDS dementia complex: an expanded series including response to zidovudine treatment. AIDS 1992; 6: 641-5
40. Elovaara I, Poutiainen E, Lahdevirta J, et al. Zidovudine reduces intrathecal immunoactivation in patients with early human immunodeficiency virus type 1 infection. Arch Neurol 1994; 51: 943-50
41. Gray F, Bélec L, Keohane C, et al. Zidovudine therapy and HIV encephalitis: a 10-year neuropathological survey. AIDS 1994; 8: 489-93
42. Vago L, Castagna A, Lazzarin A, et al. Reduced frequency of HIV-induced brain lesions in AIDS patients treated with zidovudine. J Acquir Immune Defic Syndr 1993; 6: 42-5
43. Maehlen J, Dunlop O, Liestol K, et al. Changing incidence of HIV-induced brain lesions in Oslo, 1983-1994: effects of zidovudine treatment. AIDS 1995; 9: 1165-9
44. Bell JE, Donaldson YK, Lowrie S, et al. Influence of risk group and zidovudine therapy on the development of HIV encephalitis and cognitive impairment in AIDS patients. AIDS 1996; 10: 493-9
45. Chiesi A, Vella S, Dally LG, et al. Epidemiology of AIDS dementia complex in Europe. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11: 39-44
46. Portegies P, de Gans J, Lange JMA, et al. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. BMJ 1989; 299: 819-21
47. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Ann Intern Med 1990; 112: 727-37
48. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990; 322: 941-9
49. Hamilton JD, Hartigan PM, Simberkoff MS, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. N Engl J Med 1992; 326: 437-43
50. Merigan TC, Amato DA, Balsley J, et al. Placebo-controlled trial to evaluate zidovudine in treatment of human immunodeficiency virus infection in asymptomatic patients with haemophilia. Blood 1991; 78: 900-6
51. Butler KM, Husson RN, Balis FM, et al. Dideoxyinosine in children with symptomatic human inimunodeficiency virus infection. N Engl J Med 1991; 324: 137-44
52. Portegies P, Enting RH, de Jong MD, et al. AIDS dementia complex and didanosine [letter]. Lancet 1994; 344: 759
53. Deeks SG, Smith M, Holodniy M, et al. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997; 277: 145-53
54. Crixivan product monograph. Whitehouse Station (NJ): Merck & Co, Inc., 1996: 31
55. Viramune product monograph. Ridgefield: Boehringer Ingelheim Pharmaceuticals Inc., 1996
56. Brew B, Dunbar N, Druett J, et al. Pilot study of the efficacy of atevirdine in the treatment of AIDS dementia complex. AIDS 1996; 10: 1357-60
57. Portegies P. HIV-1, the brain and combination therapy. Lancet 1995; 346: 1244-5
58. Di Stefano M, Norkrans G, Chiodi F, et al. Zidovudine-resistant variants of HIV-1 in the brain [letter]. Lancet 1993; 342: 865
59. Wildemann B, Haas J, Ehrhart K, et al. In vivo comparison of zidovudine resistant mutations in blood and CSF of HIV-1 infected patients. Neurology 1993; 43: 2659-63